ClinicalTrials.gg
RecruitingNCT06864156Updated Mar 7, 2025

Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19

An observational study in Long COVID and Long COVID Syndrome, sponsored by Instituto Nacional de Rehabilitacion. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Instituto Nacional de Rehabilitacion · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years to 65 Years
Sex
All
01

Study summary

At the moment, the number of people with long COVID is unkown because there is still no effective diagnosis. This is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. This project seeks to analyze some blood components of people with long COVID, such as microRNAs and vitamin B12, in order to identify the body processes that changed after COVID-19 and thereby design better therapies and diagnostic methods focused on each of them.

The hypothesis is that the expression of miR-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin B12 in serum in subjects suffering from long COVID with neurological symptoms of depression, anxiety and fatigue.

02

Conditions studied

  • Long COVID
  • Long COVID Syndrome

Keywords

  • anxiety
  • depression
  • fatigue
  • microRNAs
  • vitamin b12
  • long covid
03

In context

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 20 is below the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Instituto Nacional de Rehabilitacion is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects with symptoms of depression, anxiety and fatigue after having had COVID-19

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with confirmed diagnosis of COVID-19 by SARS-CoV-2 infection by PCR or antigen testing.
  • With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 after three months from the first day of acute infection symptoms.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have presented symptoms of acute infection in the last twelve weeks.
  • Subjects who present diagnostic premorbid neurological alterations.
  • Subjects who do not have at least 2 doses of COVID-19 vaccine, with last application date equal or older than 3 months.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Long COVID

    With presence of neurological symptoms of depression, anxiety and fatigue associated with COVID-19 three months after the first day with symptoms of acute infection

  • Control

    Not presented symptoms associated with COVID-19 twelve weeks after the first day with symptoms of acute infection

06

What researchers measure

Primary outcomes

  1. Change of microRNA expression between long COVID group and control group

    Time frame: immediately after the blood extraction

  2. Change of vitamin B12 concentration between long COVID group and control group

    Time frame: immediately after the blood extraction

  3. Link the expression of microRNAs with the score obtained in the instruments to evaluate depression, anxiety and fatigue

    Time frame: immediately after the blood extraction

  4. Link the concentration of vitamin B23 with the score obtained in the instruments to evaluate depression, anxiety and fatigue.

    Time frame: immediately after the blood extraction

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jul 2025, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 7, 2025
StartActual
Feb 18, 2025
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06864156
Lead sponsor
Instituto Nacional de Rehabilitacion
Responsible party
Alfonso B. Alfaro (Principal Investigator, Instituto Nacional de Rehabilitacion) — Principal investigator
First posted
Mar 7, 2025
Start date
Feb 18, 2025
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Mar 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion